Icon Genetics and Novoplant announce broad license agreement
"Icon has developed new generation production platforms that are by far more effective and safe than those commercialized today, and they are more appropriate for the kind of products that Novoplant is developing. We believe that this agreement is an important step in mutually beneficial relationship with Novoplant, and I look forward to broadening our collaboration", said Dr. Yuri Gleba, CEO of Icon Genetics.
"We believe Icon Genetics' proprietary gene transfer systems provide freedom to operate in otherwise restricted areas. Icon's Transgene Operating System® technology, combined with Novoplant technologies, is expected to provide a superior approach to rapid progress in our animal health research, product development and manufacturing," said Dr. Theodor Fahrendorf, CEO of Novoplant.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.